OncXerna Therapeutics to Present at Jefferies Virtual Healthcare Conference
18 mai 2021 08h00 HE
|
OncXerna Therapeutics, Inc.
WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to...
OncXerna Therapeutics Provides New Results from its Xerna™ RNA-based Biomarker Platform at the AACR Annual Meeting
10 avr. 2021 08h30 HE
|
OncXerna Therapeutics, Inc.
Xerna™ TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities in colorectal cancer Data supports the application of Xerna™ TME Panel beyond...
OncXerna Therapeutics to Participate at the Upcoming Investor Conferences
12 févr. 2021 07h05 HE
|
OncXerna Therapeutics, Inc.
WALTHAM, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses...
OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs
29 janv. 2021 07h05 HE
|
OncXerna Therapeutics, Inc.
WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses...
OncXerna Therapeutics to Participate at the Piper Sandler Virtual Healthcare Conference
13 nov. 2020 07h05 HE
|
OncXerna Therapeutics, Inc.
WALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to predict patient responses for...
OncXerna Therapeutics to Participate at the Jefferies Virtual London Healthcare Conference
15 oct. 2020 07h10 HE
|
OncXerna Therapeutics, Inc.
WALTHAM, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to predict patient responses for...
Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics
18 sept. 2020 07h05 HE
|
OncXerna Therapeutics, Inc.
OncXerna’s RNA-based biomarker platform successfully identified responders versus non-responders in trials with late-stage cancer patients Interim results from a Phase 2 trial of bavituximab with...
Oncologie Announces Presentation at the Morgan Stanley Annual Global Healthcare Conference
27 août 2020 07h05 HE
|
Oncologie, Inc.
WALTHAM, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Oncologie, Inc., a precision medicine company using an innovative RNA-based biomarker platform to develop novel, targeted oncology therapies, today...
Oncologie Announces Upcoming Presentations at Investor Conferences
27 juil. 2020 16h15 HE
|
Oncologie, Inc.
WALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Oncologie, Inc., a precision medicine company using an innovative RNA-based biomarker platform to develop novel, targeted oncology therapies, today...
Oncologie Expands and Strengthens Management Team with Key Appointments and Promotions
09 juil. 2020 07h00 HE
|
Oncologie, Inc.
-Appoints Matthew Osborne as Chief Financial Officer- -Names Hagop Youssoufian, M.D., as Interim Chief Medical Officer- -Hires Bill McDonald, Ph.D., as Vice President of CMC- -Promotes Kerry...